Avramis V I, Powell W
Department of Pediatrics, USC School of Medicine, Childrens Hospital of Los Angeles 90027.
Cancer Invest. 1987;5(4):293-9.
Deamination of cytosine arabinoside (ara-C) by cytidine deaminase (Cyt DA) is the main mode of the inactivation of this drug in vivo. Tetrahydrouridine (THU) and the deamination product, uracil arabinoside (ara-U) are potent inhibitors of Cyt DA. We investigated whether ara-U or THU pretreatments can protect ara-C from excessive deamination in tumor- (L1210) bearing mice. In order to determine this, plasma concentrations of ara-C, ara-U, and the intracellular levels of ara-CTP, the active anabolite of ara-C, were assayed. The control peak plasma levels of ara-C and ara-U were 3.3 and 0.78 mM and they were eliminated with a half life (t 1/2) of 1.26 and 1.43 hours, respectively. One hour pretreatment with a nontoxic dose of ara-U (single dose of 300 mg/kg intraperitoneally), resulted in increased ara-C levels by 5.9-fold, while ara-U increased 14.3 fold in comparison with controls. A 24-hour (every 8 hours) pretreatment with ara-U increased ara-C plasma levels by 3.0-fold and it was eliminated with a t 1/2 of 1.21 hours. One hour pretreatment with THU (single dose 25 mg/kg intraperitoneally) enhanced ara-C plasma levels by 5.3-fold. In control L1210/0 acid extracts, ara-CTP peaked at 2 hours and reached 2030 +/- 85 microM; ara-CTP was eliminated with a t 1/2 1.47 hours. The ara-CTP cellular concentrations after 1- and 24-hour pretreatments were 1875 +/- 534 and 2624 +/- 429 microM at 4 hours; the t 1/2 were 2.20 and 1.44 hours, respectively. The THU pretreatment resulted in a peak concentration of ara-CTP of 2208 +/- 366 microM at 2 hours and was eliminated with a t 1/2 of 2.54 hours. We concluded that all pretreatments increased both the peak plasma ara-C concentrations and the area under the plasma concentration-time curve (AUC). One hour ara-U pretreatment did not enhance the peak ara-CTP cellular concentration, but did extend the t 1/2. The 24-hour ara-U and the 1-hour THU pretreatments increased, to some extent, the cellular ara-CTP concentrations, but these differences were not statistically significant. THU pretreatment increased the time the peak occurred and the t 1/2 of ara-CTP. The area under the cellular ara-CTP concentration-time curve (AUC) in L1210 cells was either the same or increased by a small amount after the pretreatments.(ABSTRACT TRUNCATED AT 400 WORDS)
胞苷脱氨酶(Cyt DA)对阿糖胞苷(ara-C)的脱氨作用是该药物在体内失活的主要方式。四氢尿苷(THU)和脱氨产物阿糖尿苷(ara-U)是Cyt DA的有效抑制剂。我们研究了ara-U或THU预处理是否能保护荷瘤(L1210)小鼠体内的ara-C免受过度脱氨。为了确定这一点,我们检测了ara-C、ara-U的血浆浓度以及ara-C的活性代谢产物阿糖胞苷三磷酸(ara-CTP)的细胞内水平。ara-C和ara-U的对照血浆峰值水平分别为3.3和0.78 mM,它们的消除半衰期(t 1/2)分别为1.26和1.43小时。用无毒剂量的ara-U(腹腔注射单剂量300 mg/kg)预处理1小时,ara-C水平升高了5.9倍,而ara-U与对照组相比升高了14.3倍。用ara-U进行24小时(每8小时一次)预处理使ara-C血浆水平升高了3.0倍,其消除半衰期为1.21小时。用THU(腹腔注射单剂量25 mg/kg)预处理1小时使ara-C血浆水平升高了5.3倍。在对照L1210/0酸提取物中,ara-CTP在2小时达到峰值,为2030±85 microM;ara-CTP的消除半衰期为1.47小时。1小时和24小时预处理后4小时的ara-CTP细胞浓度分别为1875±534和2624±429 microM;半衰期分别为2.20和1.44小时。THU预处理使ara-CTP在2小时的峰值浓度达到2208±366 microM,并以2.54小时的半衰期消除。我们得出结论,所有预处理均提高了血浆ara-C峰值浓度和血浆浓度-时间曲线下面积(AUC)。1小时ara-U预处理未提高ara-CTP细胞峰值浓度,但延长了半衰期。24小时ara-U和1小时THU预处理在一定程度上提高了细胞内ara-CTP浓度,但这些差异无统计学意义。THU预处理增加了峰值出现的时间和ara-CTP的半衰期。预处理后L1210细胞内ara-CTP浓度-时间曲线下面积(AUC)相同或略有增加。(摘要截断于400字)